Literature DB >> 3300989

Effect of nifedipine on glucose tolerance, serum insulin, and serum fructosamine in diabetic and nondiabetic patients.

J S Gill, N Al-Hussary, A V Zezulka, K J Pasi, T W Atkins, D G Beevers.   

Abstract

The hypothesis that nifedipine may cause an insidious but reversible change in glucose tolerance, similar to that associated with thiazide therapy, was studied in six nondiabetic and six noninsulin-dependent diabetic patients with hypertension. After medium-term nifedipine therapy (mean duration, 11.5 months) was stopped for one month and then resumed for a month, values for fasting blood glucose, fasting serum insulin, serum fructosamine, glucose tolerance, and insulin release in response to oral glucose were unchanged in both groups. These findings suggest that nifedipine in conventional doses does not have important effects on glucose handling in either diabetic or nondiabetic patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300989

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

Review 1.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics.

Authors:  M Krempf; S Ranganatan; P Ritz; J M Garnier; B Charbonnel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients.

Authors:  C Ferrier; P Ferrari; P Weidmann; U Keller; C Beretta-Piccoli; W F Riesen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  Metabolic effects of lacidipine: a placebo-controlled study using the euglycaemic hyperinsulinaemic clamp.

Authors:  A D Morris; R Donnelly; J M Connell; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.